A new CRISPR diagnostic technology has been developed that can rapidly and accurately detect viruses without the need for Polymerase Chain Reaction (PCR). This technology is expected to play a significant role in enhancing the ability to respond to infectious diseases on-site in the future.


The Korea Research Institute of Bioscience and Biotechnology announced on December 12 that Dr. Kang Taejun’s research team at the Bio-Nano Research Center, in collaboration with the teams led by Dr. Woo Uijeon and Dr. Park Kwanghyun, has developed this technology.


The research team is experimenting with a new CRISPR diagnostic technology. Provided by Korea Research Institute of Bioscience and Biotechnology.

The research team is experimenting with a new CRISPR diagnostic technology. Provided by Korea Research Institute of Bioscience and Biotechnology.

View original image

The joint research team’s technology can directly detect trace amounts of viral RiboNucleic Acid (RNA) without the complex process of amplifying viral genes. By overcoming the limitations of existing PCR diagnostic methods, it is being evaluated as a next-generation platform that enables rapid, simple, and accurate diagnosis of infectious diseases.


The widely used PCR method has the disadvantage of requiring specialized equipment, skilled personnel, and a lengthy testing process because it necessitates multiple rounds of gene replication. This was one of the factors that made rapid on-site diagnosis difficult during the rapid spread of infectious diseases in the COVID-19 pandemic.


To address these issues, the joint research team focused on 'Cas12a2,' a new CRISPR enzyme that has recently attracted attention. They systematically investigated how this enzyme recognizes and reacts to viruses, ultimately identifying the most suitable operating conditions.


They also succeeded in developing a new diagnostic technology that can directly detect trace amounts of viral RNA without gene amplification.


The greatest advantage of 'Cas12a2' is its ability to detect even smaller amounts of virus more accurately than the conventional PCR method. This enzyme verifies the presence of viral RNA through a two-step confirmation process, which reduces the likelihood of false positives from irrelevant signals. It can also detect even very weak signals when targeting the virus.


To determine how accurately this technology can detect the COVID-19 virus, the joint research team analyzed the viral genome and created 11 different tools (crRNA) for virus recognition.


Experimental results showed that using four different tools simultaneously yielded the best performance. When four tools were used together, the accuracy and sensitivity of virus detection were significantly higher than when only one tool was used.


In actual experiments, the simultaneous use of four tools enabled detection of up to 1,000 times lower amounts of virus compared to existing methods.


The joint research team also conducted validation to confirm whether this technology could be applied in real infection scenarios. They performed experiments on various COVID-19 variants.


The results showed that all 26 variants, including Alpha, Delta, and Omicron, were accurately detected. Furthermore, the technology did not react at all to other viruses such as common cold coronaviruses, influenza, or MERS, demonstrating high selectivity for the target virus.


Notably, when 245 patient samples collected from actual hospitals were analyzed, the technology demonstrated 100% concordance in sensitivity and specificity with PCR tests, proving its reliability in clinical settings.


This technology developed by the joint research team also eliminates the need for separate RNA extraction. With simple heat and solution treatment, testing can be performed immediately, making it highly useful in locations requiring rapid decision-making, such as airports, ports, schools, and military bases. Its successful operation on portable devices further increases its potential as an on-site diagnostic technology for infectious diseases.


Dr. Kang stated, "This research is significant in that it enables accurate detection of viral RNA without gene amplification," adding, "Based on this, the joint research team plans to expand the technology to diagnose various infectious diseases such as influenza, RSV, and antibiotic-resistant bacteria."



Meanwhile, the results of this research were recently published online in the international scientific journal 'Nucleic Acids Research.'


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing